[Reuters] – AstraZeneca is moving an experimental Alzheimer’s drug into late-stage development, taking on U.S. rival Merck & Co which announced plans to start similar final-stage research in December. Both the AstraZeneca and Merck medicines work by blocking an enzyme called beta secretase that is involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of Alzheimer’s disease. Such oral drugs are known as BACE … [visit site to read more]
- Company Update: Pfizer Inc (NYSE:PFE) – Pfizer’s new breast cancer drug succeeds in trial
- Amgen Inc. (NASDAQ:AMGN) – Amgen cholesterol drug succeeds in late-stage trial
- Merck & Co. Inc. (NYSE:MRK) – Germany’s Merck looks for deals to lift U.S. drug sales
